Cargando…

ESR1 hotspot mutations in endometrial stromal sarcoma with high-grade transformation and endocrine treatment

High-grade endometrial stromal sarcomas (HGESSs) are more aggressive and have higher rates of resistance to endocrine therapy than low-grade endometrial stromal sarcomas (LGESSs). The pathogenesis of hormonal resistance in these lesions has yet to be defined. Here we sought to histologically and gen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dessources, Kimberly, Miller, Kathryn M, Kertowidjojo, Elizabeth, Da Cruz Paula, Arnaud, Zou, Youran, Selenica, Pier, da Silva, Edaise M, Benayed, Ryma, Ashley, Charles W, Abu-Rustum, Nadeem R, Dogan, Snjezana, Soslow, Robert A, Hensley, Martee L, Weigelt, Britta, Chiang, Sarah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234101/ https://www.ncbi.nlm.nih.gov/pubmed/34961764 http://dx.doi.org/10.1038/s41379-021-01003-5

Ejemplares similares

High-Grade Transformation of Low-Grade Endometrial Stromal Sarcomas Lacking YWHAE and BCOR Genetic Abnormalities
por: Zou, Youran, et al.
Publicado: (2020)

TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer
por: da Silva, Edaise M., et al.
Publicado: (2021)

Genomic profiling of primary and recurrent adult granulosa cell tumors of the ovary
por: Da Cruz Paula, Arnaud, et al.
Publicado: (2020)

Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy
por: Kyi, Chrisann, et al.
Publicado: (2021)

Genomic Landscape of Endometrial Carcinomas of No Specific Molecular Profile
por: Momeni-Boroujeni, Amir, et al.
Publicado: (2022)

Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary
por: Kim, Sarah H., et al.
Publicado: (2020)

A Survey of DICER1 Hotspot Mutations in Ovarian and Testicular Sex Cord-Stromal Tumors
por: Conlon, Niamh, et al.
Publicado: (2015)

De Novo ESR1 Hotspot Mutation in a Patient With Endometrial Cancer Treated With an Aromatase Inhibitor
por: Morel, Adeline, et al.
Publicado: (2019)

Genomic characterization of small cell carcinomas of the uterine cervix
por: Schultheis, Anne M., et al.
Publicado: (2021)

Retained Mismatch Repair Protein Expression Occurs in Approximately 6% of Microsatellite Instability-High Cancers and is Associated with Missense Mutations in Mismatch Repair Genes.
por: Hechtman, Jaclyn F., et al.
Publicado: (2019)

ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer
por: Lei, Jonathan T., et al.
Publicado: (2018)

Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma
por: Drouyer, Aurélien, et al.
Publicado: (2023)

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer
por: Hartmaier, R J, et al.
Publicado: (2018)

The ESR Patient Advisory Group (ESR-PAG)
Publicado: (2015)

Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer
por: Li, Zheqi, et al.
Publicado: (2022)

Leiomyoma With Bizarre Nuclei: A Morphological, Immunohistochemical and Molecular Analysis of 31 Cases
por: Bennett, Jennifer A., et al.
Publicado: (2017)

Genetic analysis of uterine adenosarcomas and phyllodes tumors of the breast
por: Geyer, Felipe C., et al.
Publicado: (2017)

XBP1 increases transactivation of somatic mutants of ESR1 and loss of XBP1 reverses endocrine resistance conferred by gain-of-function Y537S ESR1 mutation
por: Barua, David, et al.
Publicado: (2020)

Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance
por: Martin, Lesley-Ann, et al.
Publicado: (2017)

Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance
por: Li, Li, et al.
Publicado: (2020)

Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
por: Ahn, Sung Gwe, et al.
Publicado: (2022)

Immunohistochemical Analysis of IDH2 R172 Hotspot Mutations in Breast Papillary Neoplasms: Applications in the Diagnosis of Tall Cell Carcinoma with Reverse Polarity
por: Pareja, Fresia, et al.
Publicado: (2020)

Pattern of disease and response to pembrolizumab in recurrent cervical cancer
por: Miller, Kathryn M., et al.
Publicado: (2021)

ESR1 Methylation Measured in Cell-Free DNA to Evaluate Endocrine Resistance in Metastatic Breast Cancer Patients
por: Bos, Manouk K., et al.
Publicado: (2022)

ESR1 and ESR2 genotypes and the age at menarche in idiopathic scoliosis
por: Janusz, Piotr, et al.
Publicado: (2014)

The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas
por: Moukarzel, Lea A., et al.
Publicado: (2021)

Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers
por: Veeraraghavan, Harini, et al.
Publicado: (2020)

Stochastic Cooling at the ESR
por: Beckert, Karl, et al.
Publicado: (2000)

Stochastic cooling at the ESR
por: Beckert, K, et al.
Publicado: (1999)

Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas
por: Geyer, Felipe C., et al.
Publicado: (2018)

The predictive ability of plasma ESR1 mutations for the efficacy of endocrine therapy in hormone-receptor-positive advanced breast cancer
por: Du, Yangfan, et al.
Publicado: (2018)

The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy
por: De Santo, Irene, et al.
Publicado: (2019)

Author Correction: Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
por: Ahn, Sung Gwe, et al.
Publicado: (2022)

Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer
por: Gou, Xuxu, et al.
Publicado: (2021)

CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients
por: Crucitta, Stefania, et al.
Publicado: (2023)

The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers
por: Mandelker, Diana, et al.
Publicado: (2019)

ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor–Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy
por: Reinert, Tomás, et al.
Publicado: (2020)

Radiation therapy for epithelial ovarian cancer brain metastases: clinical outcomes and predictors of survival
por: Teckie, Sewit, et al.
Publicado: (2013)

Geometric network analysis provides prognostic information in patients with high grade serous carcinoma of the ovary treated with immune checkpoint inhibitors
por: Elkin, Rena, et al.
Publicado: (2021)

Loss of the BRCA1-PALB2 interaction accelerates p53-associated tumor development in mice
por: Mahdi, Amar H., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_crco6rklk17541gso7tv58bb8l